| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02943213 | Anti-Psychotic|Management of Manifestations of Psychotic Disorders|Treatment of Schizophrenia|Control Nausea and Vomiting|Relief of Restlessness and Apprehension Before Surgery|Acute Intermittent Porphyria|Adjunct in the Treatment of Tetanus|Control Manifestations of the Manic Type of Mani-depressive Illness|Relief of Intractable Hiccups | Drug: Chlorpromazine Hydrochloride | Cycle Pharmaceuticals Ltd.|Parexel | Phase 1 | 2016-11-01 | 2016-12-13 |
| NCT03021486 | Malignant Neoplasms of Independent (Primary) Multiple Sites | Drug: Haloperidol|Drug: Chlorpromazine|Behavioral: Symptom Questionnaire | M.D. Anderson Cancer Center|National Institutes of Health (NIH) | Phase 2|Phase 3 | 2017-05-01 | 2017-03-23 |
| NCT01404364 | Blind Painful Eye|Refractory Glaucoma|Control of Pain Through Drug Injection | Drug: Triamcinolone|Drug: Chlorpromazine | Hospital Governador Celso Ramos | | 2010-01-01 | 2011-07-27 |
| NCT00202293 | Bipolar Disorder|Schizoaffective Disorder | Drug: Olanzapine|Drug: Lithium|Drug: Chlorpromazine | Melbourne Health | Phase 4 | 2001-10-01 | 2015-11-18 |
| NCT00169039 | Schizophrenia | Drug: Clozapine|Drug: Chlorpromazine | Harvard Medical School|National Institute of Mental Health (NIMH)|Dartmouth-Hitchcock Medical Center|Commonwealth Research Center, Massachusetts|Novartis | Phase 4 | 1994-12-01 | 2015-04-06 |
| NCT00882518 | Schizophrenia | Drug: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Drug: Chlorpromazine | AstraZeneca | Phase 3 | 2009-04-01 | 2012-04-16 |
| NCT01509885 | Spinal Cord Injuries|Muscle Spasticity | | University of Alberta | | 2010-07-01 | 2012-11-16 |
| NCT02810782 | Neonatal Abstinence Syndrome | Drug: Phenobarbital|Drug: Chlorpromazine|Drug: Morphine | University of Zurich | Phase 3 | 2001-06-01 | 2016-06-28 |
| NCT00654576 | Schizophrenia | Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|Behavioral: psychosocial intervention | Central South University|Shanghai Mental Health Center|Sichuan University|Capital Medical University|Nanjing Medical University|Jiangxi Mental Hospital|Hunan Mental Hospital|Guangzhou Mental Hospital|Chongqing Metal Institute|Henan Mental Hospital | Phase 4 | 2005-02-01 | 2008-04-07 |
| NCT01016145 | Schizophrenia or Schizoaffective Disorder | Drug: Antipsychotics|Drug: Antipsychotics | University of Sao Paulo | Phase 4 | 2009-04-01 | 2009-11-18 |
| NCT01561742 | Schizophrenia | Drug: Minocycline|Drug: Placebo | The University of Texas Health Science Center, Houston|Stanley Medical Research Institute | | 2012-02-01 | 2012-03-22 |
| NCT01547026 | Schizophrenia|Schizo-affective Disorder | Behavioral: Implementation Intentions | University of Konstanz|Center for Psychiatry, Reichenau, Germany|Thurgau Psychiatric Services, Switzerland | | 2012-04-01 | 2013-02-12 |
| NCT00678691 | Fibromyalgia, Primary | Drug: armodafinil|Drug: placebo | State University of New York - Upstate Medical University | Phase 4 | 2007-08-01 | 2014-12-09 |
| NCT03019887 | Schizophrenia Relapse | Drug: risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine | Juntendo University | | 2011-04-01 | 2017-01-14 |
| NCT01594749 | Chemotherapy-Induced Nausea and Vomiting (CINV) | Drug: Fosaprepitant dimeglumine|Drug: Fosaprepitant Placebo|Drug: Dexamethasone|Drug: Ondansetron|Drug: Dexamethasone Placebo|Drug: Ondansetron Placebo|Drug: Rescue Therapy | Merck Sharp & Dohme Corp. | Phase 3 | 2012-09-01 | 2017-02-17 |
| NCT02582736 | Psychotic Disorders|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder|Diabetes Mellitus, Type 2 | Drug: Olanzapine|Drug: Risperidone|Drug: atypical antipsychotics (other)|Drug: typical antipsychotics | Canadian Network for Observational Drug Effect Studies, CNODES|Drug Safety and Effectiveness Network, Canada|Canadian Institutes of Health Research (CIHR) | | 2012-04-01 | 2015-10-20 |
